ARTICLE | Deals
Deals Report: Novo Nordisk tapping NanoVation delivery tech, Organon acquires Dermavant, Telix expands U.S. radiopharma footprint, and more
By Gunjan Ohri, Data Content Analyst
September 24, 2024 1:23 AM UTC
Sanofi has done two deals in three months that show it’s willing to extend its neuro-immunology focus beyond its comfort zone of multiple sclerosis. In both cases, it made tentative moves via equity investments in biotechs.
In its latest deal, announced Monday, Sanofi (Euronext:SAN; NASDAQ:SNY) made a $27 million equity investment in Ventyx Biosciences Inc. (NASDAQ:VTYX), gaining right of first negotiation for VTX3232, a CNS-penetrant inhibitor of innate immune target NLRP3, which is in Phase II trials for Parkinson’s disease and obesity. Data from both studies are expected in 2025. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653650/ventyx-deal-a-sign-of-sanofi-s-growing-interest-neuro-immunology